NanoViricides Inc. (NNVC)

[changes_iv]

According to a company statement issued earlier in the week, NanoViricides believes that simultaneously testing of the drug candidates at these two sites should result in a dataset yielding a "high degree of confidence". Its FluCide drug has the potential to wipe out virtually all strains of the influenza A virus. Toxicology studies are expected to be wrapped up before mid-2014.

source: http://www.proactiveinvestors.com/companies/news/46906/nanoviricides-stock-up-almost-20-hits-new-52-week-high-on-back-of-nda-46906.html

Can you find anything wrong with the statement above?

In addition to FluCide, New Mexico-based Lovelace will be allowed to test the company's candidate for MERS (Middle East Respiratory Syndrome) – an ailment named as a potential threat to public health and national security by the Obama administration in June.

The news follows the recent execution of another NDA with the UK Public Health Agency for the testing of its FluCide candidate against the A/H7N9 strain as well as new drug candidates against the emerging MERS virus.